{
  "id": "5324a8ac9b2d7acc7e000018",
  "type": "factoid",
  "question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?",
  "ideal_answer": "The fusion protein BCR-ABL",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16757427",
    "http://www.ncbi.nlm.nih.gov/pubmed/22037271",
    "http://www.ncbi.nlm.nih.gov/pubmed/23090888",
    "http://www.ncbi.nlm.nih.gov/pubmed/21903771",
    "http://www.ncbi.nlm.nih.gov/pubmed/21279819",
    "http://www.ncbi.nlm.nih.gov/pubmed/23285088",
    "http://www.ncbi.nlm.nih.gov/pubmed/22985168",
    "http://www.ncbi.nlm.nih.gov/pubmed/17379100",
    "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
    "http://www.ncbi.nlm.nih.gov/pubmed/19641300",
    "http://www.ncbi.nlm.nih.gov/pubmed/22895079",
    "http://www.ncbi.nlm.nih.gov/pubmed/14639002",
    "http://www.ncbi.nlm.nih.gov/pubmed/12755554",
    "http://www.ncbi.nlm.nih.gov/pubmed/20875546",
    "http://www.ncbi.nlm.nih.gov/pubmed/22160058",
    "http://www.ncbi.nlm.nih.gov/pubmed/16850123",
    "http://www.ncbi.nlm.nih.gov/pubmed/20425400",
    "http://www.ncbi.nlm.nih.gov/pubmed/22460758",
    "http://www.ncbi.nlm.nih.gov/pubmed/21672900",
    "http://www.ncbi.nlm.nih.gov/pubmed/22461032",
    "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
    "http://www.ncbi.nlm.nih.gov/pubmed/21892537",
    "http://www.ncbi.nlm.nih.gov/pubmed/12796373",
    "http://www.ncbi.nlm.nih.gov/pubmed/12783369",
    "http://www.ncbi.nlm.nih.gov/pubmed/18974832",
    "http://www.ncbi.nlm.nih.gov/pubmed/23174189",
    "http://www.ncbi.nlm.nih.gov/pubmed/22087818",
    "http://www.ncbi.nlm.nih.gov/pubmed/22052279",
    "http://www.ncbi.nlm.nih.gov/pubmed/17382020",
    "http://www.ncbi.nlm.nih.gov/pubmed/22191306",
    "http://www.ncbi.nlm.nih.gov/pubmed/23942795",
    "http://www.ncbi.nlm.nih.gov/pubmed/22349810",
    "http://www.ncbi.nlm.nih.gov/pubmed/19075651",
    "http://www.ncbi.nlm.nih.gov/pubmed/23666688",
    "http://www.ncbi.nlm.nih.gov/pubmed/16146726",
    "http://www.ncbi.nlm.nih.gov/pubmed/17956348",
    "http://www.ncbi.nlm.nih.gov/pubmed/11870241",
    "http://www.ncbi.nlm.nih.gov/pubmed/21672337",
    "http://www.ncbi.nlm.nih.gov/pubmed/15739279",
    "http://www.ncbi.nlm.nih.gov/pubmed/12869662",
    "http://www.ncbi.nlm.nih.gov/pubmed/17292736",
    "http://www.ncbi.nlm.nih.gov/pubmed/16988930",
    "http://www.ncbi.nlm.nih.gov/pubmed/12411298",
    "http://www.ncbi.nlm.nih.gov/pubmed/23032801",
    "http://www.ncbi.nlm.nih.gov/pubmed/21203982",
    "http://www.ncbi.nlm.nih.gov/pubmed/23233201",
    "http://www.ncbi.nlm.nih.gov/pubmed/12173333",
    "http://www.ncbi.nlm.nih.gov/pubmed/17970609",
    "http://www.ncbi.nlm.nih.gov/pubmed/20529808",
    "http://www.ncbi.nlm.nih.gov/pubmed/15899391",
    "http://www.ncbi.nlm.nih.gov/pubmed/15027317",
    "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
    "http://www.ncbi.nlm.nih.gov/pubmed/21061842",
    "http://www.ncbi.nlm.nih.gov/pubmed/19064740",
    "http://www.ncbi.nlm.nih.gov/pubmed/12176881",
    "http://www.ncbi.nlm.nih.gov/pubmed/22519766",
    "http://www.ncbi.nlm.nih.gov/pubmed/20425355",
    "http://www.ncbi.nlm.nih.gov/pubmed/18205699",
    "http://www.ncbi.nlm.nih.gov/pubmed/14744784",
    "http://www.ncbi.nlm.nih.gov/pubmed/18533795",
    "http://www.ncbi.nlm.nih.gov/pubmed/22151181",
    "http://www.ncbi.nlm.nih.gov/pubmed/17382013",
    "http://www.ncbi.nlm.nih.gov/pubmed/12750692",
    "http://www.ncbi.nlm.nih.gov/pubmed/17671641",
    "http://www.ncbi.nlm.nih.gov/pubmed/22761178",
    "http://www.ncbi.nlm.nih.gov/pubmed/16475128",
    "http://www.ncbi.nlm.nih.gov/pubmed/12200353",
    "http://www.ncbi.nlm.nih.gov/pubmed/15791812",
    "http://www.ncbi.nlm.nih.gov/pubmed/16689455",
    "http://www.ncbi.nlm.nih.gov/pubmed/22506320",
    "http://www.ncbi.nlm.nih.gov/pubmed/11986206",
    "http://www.ncbi.nlm.nih.gov/pubmed/22893108",
    "http://www.ncbi.nlm.nih.gov/pubmed/16843101",
    "http://www.ncbi.nlm.nih.gov/pubmed/19860186",
    "http://www.ncbi.nlm.nih.gov/pubmed/20607973",
    "http://www.ncbi.nlm.nih.gov/pubmed/19254884",
    "http://www.ncbi.nlm.nih.gov/pubmed/20945321",
    "http://www.ncbi.nlm.nih.gov/pubmed/12454739",
    "http://www.ncbi.nlm.nih.gov/pubmed/17929114"
  ],
  "snippets": [
    {
      "text": "CR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11), Philadelphia chromosome] creates a BCR-ABL1 fusion protein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib i",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23285088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The BCR/ABL fusion tyrosine kinase is expressed in chronic myeloid leukemia and Philadelphia-positive (Ph+) acute lymphoblastic leukemia cells, and its inhibition by the clinically used tyrosine kinase inhibitors imatinib ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23233201",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tyrosine kinase inhibitors (TKIs), imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032801",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ABL-kinase inhibitors (AKIs) Imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " BCR-ABL tyrosine kinase inhibitor imatinib ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib was the first BCR-ABL tyrosine kinase inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate, an orally available BCR-ABL kinase inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22519766",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) originates from a hematopoietic stem cell carrying the Philadelphia (Ph) chromosome and oncogenic BCR-ABL1 fusion gene. The first tyrosine-kinase inhibitor (TKI) imatinib ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22506320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "chronic myeloid leukemia (CML) patients ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22460758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22349810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22191306",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The development of first-generation (imatinib) and second-generation (dasatinib and nilotinib) tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 fusion protein produced by the Ph chromosome revolutionized the treatment of chronic myelogenous leukemia (CML).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22160058",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be successfully targeted with the BCRABL- inhibitors imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22087818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Philadelphia chromosome positive chronic myelogenous leukemia (CML) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22037271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCR-ABL levels",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "imatinib therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The discovery of targeted tyrosine kinase inhibition of BCR-ABL kinase dramatically changed the treatment of CML. Imatinib, the first TKI approved for treatment of patients with Philadelphia chromosome--positive CML",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672337",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21203982",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib (Glivec, Gleevec), a specific small molecule inhibitor of Bcr-Abl, has become the standard drug therapy for CML,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17379100",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "emergence of imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16988930",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16850123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the presence of a BCR-ABL fusion gene, which is the result of a reciprocal translocation between chromosomes 9 and 22, and is cytogenetically visible as a shortened chromosome 22 (Philadelphia)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "imatinib mesylate was introduced into the treatment regimen for CML",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757427",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hronic myelogenous leukemia is characterized by the Philadelphia-chromosome, a shortened chromosome 22 which is the result of a reciprocal translocation between chromosome 9 and 22. The fusion gene is called BCR-ABL. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate (Glivec) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16475128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hronic myeloid leukemia cells contain a BCR-ABL oncoprotein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20945321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "original TKI, imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CM",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20607973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph) that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase (TK). The introduction of imatinib, a TK inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529808",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is a paradigm for neoplasias that are defined by a unique genetic aberration, the BCR-ABL1 fusion gene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "protein tyrosine kinase inhibitor, imatinib,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML patients with imatinib treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the presence of the Philadelphia chromosome (Ph), a genetic aberration that codes for bcrabl, which plays a key role in disease pathophysiology. The first oral inhibitor of Brc-Abl was imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19254884",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two new genes, BCR-ABL on the 22q- (Ph chromosome) and the reciprocal ABL-BCR on 9q-. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tyrosine kinase inhibitor (TKI), introduced into clinical practice in 1998, was imatinib mesylate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19064740",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CR-ABL tyrosine kinase inhibitors, such as imatinib (Gleevec) are highly effective in treating human Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18205699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCR-ABL fusion protein that arises from the translocation of chromosomes 9 and 22",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCR-ABL inhibitors, such as imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate),",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop molecular-targeted therapies. Imatinib mesylate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425355",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15899391",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15791812",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML was the first human cancer demonstrated to be strongly associated to the presence of a recurrent chromosomal translocation (the t(9;22)(q34;q11) that creates the Philadelphia (Ph)-chromosome) and to a specific molecular defect, the formation of a hybrid BCR-ABL gene ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "imatinib, (Glivec, Gleevec, Novartis), a potent tyrosine kinase inhibitor of the Bcr-Abl protein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027317",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IM) binds to the BCR-ABL protein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14744784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12796373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The kinase inhibitor imatinib mesylate (Gleevec)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hiladelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "imatinib mesylate (Gleevec,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12750692",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "matinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12454739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor of Bcr-Abl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12411298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200353",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12176881",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12173333",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is characterised by the occurrence of the Philadelphia (Ph) chromosome (9/22 translocation) and the formation of a fusion protein--the BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase and consequent changes in the intracellular signal transduction, which is responsible for the deregulated myeloid cell proliferation. STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11986206",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11870241",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010677",
    "http://www.biosemantics.org/jochem#4275840",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011505",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016044",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015464",
    "http://www.disease-ontology.org/api/metadata/DOID:8552"
  ],
  "exact_answer": "BCR-ABL"
}